Share Kathleen Moore, MD, MS, FASCO, Debra Richardson, MD - Current and Future Treatment of Platinum-Resistant Ovarian Cancer With ADCs: Implications of Targeting CDH6

Copy link

September 30, 2025

Kathleen Moore, MD, MS, FASCO, Debra Richardson, MD - Current and Future Treatment of Platinum-Resistant Ovarian Cancer With ADCs: Implications of Targeting CDH6

17 minutes

Please visit answersincme.com/YMJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in gynecologic oncology discuss the evolving clinical roles of antibody–drug conjugates (ADCs) in ovarian cancer, focusing on CDH6-targeted ADCs. Upon completion of this activity, participants should be better able to: Identify the rationale for using antibody–drug conjugates (ADCs) in the treatment of platinum-resistant ovarian cancer (PROC); Evaluate the evidence for emerging CDH6-targeted ADCs in the treatment of patients with PROC; Outline expected clinical implications of the evidence for emerging CDH6-targeted ADCs in the treatment of PROC.

...more